Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.O)

CPRX.O on Consolidated Issue listed on NASDAQ Capital Market

3.43USD
16 Feb 2018
Change (% chg)

$-0.10 (-2.83%)
Prev Close
$3.53
Open
$3.50
Day's High
$3.59
Day's Low
$3.42
Volume
315,835
Avg. Vol
1,022,110
52-wk High
$4.51
52-wk Low
$1.08

Latest Key Developments (Source: Significant Developments)

Catalyst Pharmaceuticals updates on trial for patients with congenital myasthenic syndromes
Thursday, 8 Dec 2016 08:03am EST 

Catalyst Pharmaceuticals Inc : Allowing Adult CMS patients to participate in trial . "Continue to believe that we will report top-line results from this study in second half of 2017" . Number of patients increased to approximately 20 .Provides update on its clinical trial for patients with congenital myasthenic syndromes.  Full Article

Catalyst Pharmaceuticals gets FDA special protocol assessment for phase 3 trial of lems treatment
Monday, 31 Oct 2016 08:03am EDT 

Catalyst Pharmaceuticals Inc : Says intends to conduct its second phase 3 trial (designated as lms-003) at two clinical trial sites . FDA has agreed to allow Catalyst to enroll patients from its expanded access program as study subjects in this second trial .Receives special protocol assessment (SPA) from the FDA for second phase 3 clinical trial evaluating firdapse for the treatment of lems.  Full Article

Catalyst Pharmaceuticals announce Q2 2016 financial results and provides product development update
Tuesday, 9 Aug 2016 04:17pm EDT 

Catalyst Pharmaceuticals Inc : Catalyst Pharmaceuticals announces second quarter 2016 financial results and provides product development update . Q2 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S . Q2 GAAP loss per share $0.06 .Q2 non-GAAP loss per share $0.06 excluding items.  Full Article

Catalyst Pharma finalizes late-stage trial design with FDA for Firdapse
Monday, 13 Jun 2016 08:31am EDT 

Catalyst Pharmaceuticals Inc : Catalyst Pharmaceuticals announces agreement with FDA on confirmatory phase 3 study protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome . Expects to initiate a small, single-center study with Firdapse during second half of 2016 .Existing capital resources are adequate to get us to an accepted NDA submission without need for additional financing.  Full Article

Catalyst Pharmaceuticals announces reduction in workforce
Tuesday, 17 May 2016 08:03am EDT 

Catalyst Pharmaceuticals Inc : Announces reduction in workforce as part of operating expense management plan . Reducing its workforce by approximately 30% . Expects to complete reduction in workforce immediately . Reduction in workforce affects employees from Catalyst's commercial team . Believe currently available resources will be sufficient to complete development of and refile NDA for firdapse for lems, cms .Reduction in workforce is part of ongoing efforts to conserve cash to complete requirements for NDA submission of Firdapse.  Full Article

Catalyst Pharmaceuticals posts Q1 GAAP loss of $0.07/shr
Tuesday, 10 May 2016 04:56pm EDT 

Catalyst Pharmaceuticals Inc : Believe current resources give sufficient runway for at least next year . Continue to believe available resources will be sufficient to complete development of firdapse, refile nda for firdapse . Catalyst pharmaceuticals announces first quarter 2016 financial results and provides corporate update . Q1 gaap loss per share $0.07 . Q1 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S .Q1 non-gaap loss per share $0.07 excluding items.  Full Article